What is Zacks Research’s Estimate for ACAD Q2 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Investment analysts at Zacks Research reduced their Q2 2025 EPS estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 28th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings per share of $0.14 for the quarter, down from their prior forecast of $0.19. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ Q3 2025 earnings at $0.14 EPS, Q4 2025 earnings at $0.13 EPS, Q2 2026 earnings at $0.19 EPS and Q1 2027 earnings at $0.24 EPS.

A number of other equities research analysts also recently weighed in on ACAD. Deutsche Bank Aktiengesellschaft raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the company from $20.00 to $35.00 in a research note on Wednesday, May 21st. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Needham & Company LLC lifted their price target on shares of ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, May 19th. Wall Street Zen raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 21st. Finally, UBS Group decreased their price target on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, April 28th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $26.83.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD opened at $21.60 on Thursday. The firm’s 50 day simple moving average is $16.87 and its 200 day simple moving average is $17.48. The company has a market capitalization of $3.62 billion, a P/E ratio of 27.69 and a beta of 0.47. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $25.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. The business had revenue of $244.32 million for the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. ACADIA Pharmaceuticals’s quarterly revenue was up 18.7% on a year-over-year basis. During the same period last year, the firm posted $0.10 earnings per share.

Insider Buying and Selling

In related news, EVP Mark C. Schneyer sold 3,498 shares of ACADIA Pharmaceuticals stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $14.60, for a total value of $51,070.80. Following the sale, the executive vice president now owns 62,773 shares in the company, valued at $916,485.80. The trade was a 5.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the sale, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. This trade represents a 21.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,746 shares of company stock valued at $428,221 over the last three months. 28.30% of the stock is owned by company insiders.

Institutional Trading of ACADIA Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ACAD. Barclays PLC boosted its holdings in ACADIA Pharmaceuticals by 126.2% in the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock valued at $4,269,000 after acquiring an additional 154,854 shares in the last quarter. KBC Group NV boosted its holdings in shares of ACADIA Pharmaceuticals by 67.0% during the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 2,044 shares in the last quarter. R Squared Ltd bought a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at $47,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of ACADIA Pharmaceuticals by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 35,281 shares of the biopharmaceutical company’s stock valued at $647,000 after buying an additional 3,378 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of ACADIA Pharmaceuticals by 10.9% during the 4th quarter. Principal Financial Group Inc. now owns 143,694 shares of the biopharmaceutical company’s stock valued at $2,637,000 after buying an additional 14,143 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.